n-methyl-3,4-methylenedioxyamphetamine has been researched along with Chronic Disease in 18 studies
N-Methyl-3,4-methylenedioxyamphetamine: An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
3,4-methylenedioxymethamphetamine : A member of the class of benzodioxoles that is 1,3-benzodioxole substituted by a 2-(methylamino)propyl group at position 5.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chronic effects of MDMA abuse on seizure threshold have not been explored in detail so far." | 2.43 | MDMA and seizures: a dangerous liaison? ( Fornai, F; Giorgi, FS; Iudice, A; Lazzeri, G; Murri, L; Natale, G; Paparelli, A; Ruggieri, S, 2006) |
| " However, reports of adverse effects and fatalities have increased in the medical and popular press." | 2.41 | Agony and ecstasy: a review of MDMA effects and toxicity. ( Burgess, C; Gill, M; O'Donohoe, A, 2000) |
| "Chronic posttraumatic stress disorder (PTSD) is a disabling condition that generates considerable morbidity, mortality, and both medical and indirect social costs." | 1.56 | The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD. ( Doblin, R; Kahn, JG; Marseille, E; Yazar-Klosinski, B, 2020) |
| "We report a case of neurogenic bladder and chronic urinary retention associated with MDMA abuse." | 1.35 | Neurogenic bladder and chronic urinary retention associated with MDMA abuse. ( Barrueto, F; Beuerle, JR, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 11 (61.11) | 29.6817 |
| 2010's | 3 (16.67) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Greif, A | 1 |
| Šurkala, M | 1 |
| Marseille, E | 1 |
| Kahn, JG | 1 |
| Yazar-Klosinski, B | 1 |
| Doblin, R | 2 |
| Wunderli, MD | 1 |
| Vonmoos, M | 1 |
| Fürst, M | 1 |
| Schädelin, K | 1 |
| Kraemer, T | 1 |
| Baumgartner, MR | 1 |
| Seifritz, E | 1 |
| Quednow, BB | 1 |
| Beuerle, JR | 1 |
| Barrueto, F | 1 |
| Bouso, JC | 1 |
| Farré, M | 1 |
| Alcázar, MA | 1 |
| Gómez-Jarabo, G | 1 |
| León, LA | 1 |
| Landeira-Fernandez, J | 1 |
| Cardenas, FP | 1 |
| Kish, SJ | 2 |
| Lerch, J | 1 |
| Furukawa, Y | 1 |
| Tong, J | 1 |
| McCluskey, T | 1 |
| Wilkins, D | 1 |
| Houle, S | 1 |
| Meyer, J | 1 |
| Mundo, E | 1 |
| Wilson, AA | 1 |
| Rusjan, PM | 1 |
| Saint-Cyr, JA | 1 |
| Guttman, M | 1 |
| Collins, DL | 1 |
| Shapiro, C | 1 |
| Warsh, JJ | 1 |
| Boileau, I | 1 |
| Halpern, JH | 1 |
| Sherwood, AR | 1 |
| Hudson, JI | 1 |
| Gruber, S | 1 |
| Kozin, D | 1 |
| Pope, HG | 1 |
| Clatts, MC | 1 |
| Goldsamt, LA | 1 |
| Yi, H | 1 |
| Dafters, RI | 1 |
| Outslay, MG | 1 |
| Giorgi, FS | 1 |
| Lazzeri, G | 1 |
| Natale, G | 1 |
| Iudice, A | 1 |
| Ruggieri, S | 1 |
| Paparelli, A | 1 |
| Murri, L | 1 |
| Fornai, F | 1 |
| Green, AR | 1 |
| Goodwin, GM | 1 |
| McGuire, P | 1 |
| Burgess, C | 1 |
| O'Donohoe, A | 1 |
| Gill, M | 1 |
| Rogers, RD | 1 |
| Robbins, TW | 1 |
| Schifano, F | 1 |
7 reviews available for n-methyl-3,4-methylenedioxyamphetamine and Chronic Disease
| Article | Year |
|---|---|
Compassionate use of psychedelics.
Topics: Chronic Disease; Compassionate Use Trials; Hallucinogens; Humans; Mental Disorders; N-Methyl-3,4-met | 2020 |
Understanding ecstasy.
Topics: Acute Disease; Amphetamine-Related Disorders; Central Nervous System Stimulants; Chronic Disease; Co | 2006 |
MDMA and seizures: a dangerous liaison?
Topics: Acute Disease; Animals; Chronic Disease; Disease Susceptibility; Drug Interactions; Hallucinogens; K | 2006 |
Long term psychiatric and cognitive effects of MDMA use.
Topics: Chronic Disease; Cognition Disorders; Hallucinogens; Humans; Memory Disorders; Mental Recall; N-Meth | 2000 |
Agony and ecstasy: a review of MDMA effects and toxicity.
Topics: Acute Disease; Animals; Arrhythmias, Cardiac; Chronic Disease; Fever; Hallucinogens; Humans; Hyponat | 2000 |
Investigating the neurocognitive deficits associated with chronic drug misuse.
Topics: Animals; Chronic Disease; Cocaine-Related Disorders; Cognition Disorders; Humans; Marijuana Abuse; N | 2001 |
How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy?
Topics: Brain; Brain Chemistry; Chronic Disease; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetami | 2002 |
1 trial available for n-methyl-3,4-methylenedioxyamphetamine and Chronic Disease
| Article | Year |
|---|---|
MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder.
Topics: Adult; Chronic Disease; Combined Modality Therapy; Dose-Response Relationship, Drug; Double-Blind Me | 2008 |
10 other studies available for n-methyl-3,4-methylenedioxyamphetamine and Chronic Disease
| Article | Year |
|---|---|
The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD.
Topics: Adult; Chronic Disease; Clinical Trials, Phase II as Topic; Cost-Benefit Analysis; Double-Blind Meth | 2020 |
Discrete memory impairments in largely pure chronic users of MDMA.
Topics: Adult; Amphetamine-Related Disorders; Chronic Disease; Comorbidity; Female; Hair; Hallucinogens; Hum | 2017 |
Neurogenic bladder and chronic urinary retention associated with MDMA abuse.
Topics: Adult; Amphetamine-Related Disorders; Anti-Infective Agents, Urinary; Bethanechol; Central Nervous S | 2008 |
Effects of chronic intracerebroventricular 3,4-methylenedioxy-N-methamphetamine (MDMA) or fluoxetine on the active avoidance test in rats with or without exposure to mild chronic stress.
Topics: Analysis of Variance; Animals; Avoidance Learning; Chronic Disease; Depression; Disease Models, Anim | 2009 |
Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study.
Topics: Adult; Amphetamine-Related Disorders; Benzylamines; Brain; Carbon Radioisotopes; Cerebral Cortex; Ch | 2010 |
Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs.
Topics: Adolescent; Adult; Case-Control Studies; Chronic Disease; Cognition; Cognition Disorders; Confoundin | 2011 |
Club drug use among young men who have sex with men in NYC: a preliminary epidemiological profile.
Topics: Adolescent; Adult; Anesthetics, Dissociative; Central Nervous System Stimulants; Chronic Disease; Cr | 2005 |
Chronic ecstasy (MDMA) use is associated with deficits in task-switching but not inhibition or memory updating executive functions.
Topics: Adult; Chronic Disease; Cognition Disorders; Female; Humans; Inhibition, Psychological; Male; Memory | 2006 |
Ecstasy and neurodegeneration.
Topics: Brain Diseases; Chronic Disease; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Nerv | 1996 |
Chronic atypical psychosis associated with MDMA ("ecstasy") abuse.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Chronic Disease; Humans; Male; N-Methyl-3,4-methylenedioxyamph | 1991 |